GVR Report cover Electrophysiology Devices Market Size, Share & Trends Report

Electrophysiology Devices Market Size, Share & Trends Analysis Report By Device Type, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: 978-1-68038-274-7
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2022
  • Industry: Healthcare

Electrophysiology Devices Market Trends

The global electrophysiology devices market size was estimated at USD 10.07 billion in 2023 and is expected to expand at a CAGR of 13.9% from 2024 to 2030. Increasing use of electrophysiology (EP) tests in treatment and diagnosis of heart diseases, such as atrial fibrillation, growing demand for devices for cardiac rhythm management for constant monitoring, and increasing application of these devices in out-of-hospital settings are propelling the industry growth. The prevalence of heart failure, cardiac arrest, and atrial fibrillation among millennials is rising due to sedentary lifestyles, smoking, excessive alcohol consumption, and others. According to the CDC, approximately 12.1 million Americans will be suffering from atrial fibrillation by 2030.

U.S. Electrophysiology Devices market size and growth rate, 2024 - 2030

In addition, European people are more prone to atrial fibrillation than African Americans. As per the European Society of Cardiology, sudden cardiac arrest due to abnormal heart rhythm is one of the reasons for death in Western countries. It affects approximately 1 in 1,000 inhabitants per year. Electrophysiology devices are cardiology specialty equipment used mainly in the diagnosis and treatment of cardiac arrhythmias. Thus, the increasing prevalence of heart diseases is augmenting the market growth. EP has facilitated the use of mobile cardiac telemetry and ambulatory ECG monitoring. Technological advancements, such as remote monitoring of implantable cardiac devices, data storage in the cloud, and the incorporation of wireless transmission, are expected to propel market growth.

For instance, in May 2019, Biosense Webster launched the CARTONET platform, a novel cloud-based network that interconnects myriad devices and transfers the data that is utilized during the practice. It aids the healthcare providers to access the patient’s information, such as 3D images and videos, which are obtained during the ablation procedures. In recent years, the shift of patients towards minimally invasive surgeries has increased. The introduction of minimally invasive technologies, such as cryoablation, laser ablation, ultrasound ablation, and advanced mapping technologies, is also expected to bode well with the industry. For instance, in February 2022, Medtronic received U.S. FDA approval for the Freezor & Freezor Xtra, Cardiac Cryoablation Focal Catheters for the treatment of Atrioventricular Nodal Reentrant Tachycardia (AVNRT) in pediatric patients.

Market Concentration & Characteristics 

The EP devices market is highly consolidated, with leading players acquiring small and niche companies. The market growth stage is high and the pace of market growth is accelerating.

Electrophysiology Devices Market Concentration & Characteristics

The market is witnessing continuous research and development, such as the adoption of 3D mapping systems, the production of wireless and wearable devices for continuous monitoring, and the integration of artificial intelligence (AI) in electrophysiology procedures. Manufacturers are focusing on introducing novel technologies to produce more accurate, cost-effective, and user-friendly EP devices.

The electrophysiology devices market is characterized by a high level of M&A activities. The main reason for the frequent acquisitions in this market is technological soundness of small players with their robust product pipelines. It allows the key players to improve their market share, expand their product portfolio, and provide opportunities to be the first entrant into a niche market segment.

The stringent regulatory framework for approval and commercialization of electrophysiology devices impedes market growth. Compliance with regulatory standards further increases overall innovation, manufacturing, and development costs.

This market gives companies the opportunity to expand their geographic presence and product portfolios through strategic partnerships and product launches. The market participants are collaborating with healthcare providers and research institutes to research and develop niche EP devices.

The EP market has noticed a considerable rise in end-user concentration in past decade. With increasing prevalence of cardiovascular diseases, rising cases of neurological disorders, such as epilepsy, Parkinson’s disease, etc., and growing geriatric population globally, the market is growing further. Whether Inpatient Facilities, Ambulatory Surgery Centers (ASCs), or other healthcare centers are adopting advanced ablation technologies for improved procedural accuracy and patient outcomes.

Device Type Insights

Based on device type, the ablation catheters segment accounted for the largest revenue share of 45.6% in 2023. An ablation catheter is used to control irregular heartbeats that cannot be treated with medication. The ablation catheters segment comprises radiofrequency (RF) ablation, cryoablation, and pulse field ablation. Growing heart failure and arrhythmia incidences, awareness regarding the electrophysiology procedures’ reliability, advancement in EP technologies, and increasing minimally invasive procedures are factors responsible for the dominance of the segment. For instance, in January 2022, Abbott received approval for EnSite X EP System with EnSite omnipolar technology from the U.S. FDA for cardiac arrhythmias treatment.

The diagnostic catheters segment is anticipated to register a significant CAGR during the forecast period. Diagnostic catheters are used to investigate and evaluate patients with suspected cardiovascular diseases. These comprise EP mapping devices, cardiac output catheters, angiography catheters, and others. In November 2021, Koninklijke Philips N.V. acquired Cardiologs, a medical technology firm based in France. The acquisition was to expand cardiac monitoring and diagnostics portfolio of Philips with the company’s AI and cloud technology.

Indication Insights

The atrial fibrillation segment dominated the market in 2023 and accounted for the maximum revenue share of 62.2%. It is the most common type of arrhythmia associated with a high risk of stroke and blood clotting. According to the British Heart Association, in 2022, approximately 1.5 million of the UK population will suffer from atrial fibrillation. In addition, an expected 270,000 individuals aged 65 years and above have undiagnosed atrial fibrillation in the country. The high prevalence of the disease is responsible for the prominent share of the segment.

In recent years, innovative smartphone applications have been introduced for arrhythmic patients that can connect them with healthcare professionals. Moreover, Inpatient Facilities and clinical settings are taking initiative to involve arrhythmia care in their treatment routine. In May 2018, UNC AFib Care Network launched a new clinic for atrial fibrillation patients - AFib Integrated Care Clinic.

End-use Insights

The inpatient facility segment accounted for the highest share of 81.7% of the global revenue in 2023. The adoption of technologically advanced cardiac rhythm management and EP systems by interventional cardiologists and the rising burden of Cardiovascular Disease(CVD) is responsible for the dominant share of the segment. As per a study published in April 2018, daily short-term rhythm strip recordings identified an increase of 13.0% in the elderly population hospitalized for atrial fibrillation, leading to an overall prevalence of 46.0% in hospitalized patients.

The outpatient facilities segment is projected to grow at the fastest CAGR during the forecast period. A shift towards minimally invasive outpatient procedures and significant cost savings are augmenting the segment growth. For instance, a study by Health Affairs revealed that ASC procedures are cost and time-effective. It takes around 25% less time compared to the Inpatient Facilities, with USD 360 to 1,000 savings per patient owing to the lesser fixed costs. Furthermore, government initiatives to reduce the cost of treatment and favor reimbursement policies are propelling the segment growth. The Centers for Medicare & Medicaid Services (CMS) extended ambulatory surgical coverage for cardiac interventional procedures, such as pacemaker implants, endovenous ablation, and catheterization procedures.

Regional Insights

North America dominated the industry in 2023 and accounted for the maximum share of 48.3% of the global revenue due to the high cases of heart failure, cardiac arrest, and cardiac arrhythmia. The presence of sophisticated healthcare infrastructure and favorable reimbursement policies are expected to drive the region’s growth during the forecast period.

Global electrophysiology devices Market share and size, 2023

The market in Asia Pacific is estimated to witness the fastest growth rate during the forecast period. The high geriatric population, growing risk of heart diseases, and unmet clinical needs are primary factors driving the region’s growth.

Furthermore, improving healthcare infrastructure, increasing patient awareness, and rising healthcare expenditure levels in the region are expected to assist manufacturers in capitalizing on these available opportunities. Rapid developments in healthcare infrastructure and an increase in disposable income in emerging economies, such as India and China, are projected to boost the demand for EP systems. Moreover, technological advancements in the region are another factor contributing to the market growth. For instance, in August 2021, Shanghai Microport EP Medtech Co., Ltd. collaborated with Stereotaxis, Inc. Under the terms of the agreement, Microport EP will be distributing Robotic Magnetic Navigation technology for EP in China.

Key Electrophysiology Devices Company Insights

The market is highly competitive with companies adhering to new product development and extensive R&D investments as sustainability strategies. Globally, companies are following an inorganic growth strategy for strengthening product portfolios and establishing a foothold in the industry. The untapped emerging markets in Asian countries like India and China offer a great opportunity to investors for expansion in the region.

Some key players operating in the market include Boston Scientific Corp., Medtronic, and Abbott.

  • Boston Scientific Corp offers a broad portfolio of less-invasive medical technologies covering the areas of cardiac rhythm management, electrophysiology, endoscopy, interventional cardiology therapies, neuromodulation, peripheral interventions, urology, and WATCHMAN. The company has various mapping and treatment technologies to diagnose and treat heart rhythm disorders.

  • Abbott provides healthcare technologies spread over cardiovascular care, diabetes care, diagnostics, neuromodulation care, nutrition, and branded generic medicines. The company is known for some of its featured brands, such as Similac, PediaSure, Ensure, and Pedialyte.

Key Electrophysiology Devices Companies:

The following are the leading companies in the electrophysiology devices market. These companies collectively hold the largest market share and dictate industry trends.

  • Boston Scientific Corp.
  • Medtronic
  • Abbott
  • Biosense Webster (Johnson & Johnson Services, Inc.)
  • Biotronik
  • General Electric Company
  • Siemens Healthcare AG
  • MicroPort Scientific Corporation
  • Koninklijke Philips N.V.

Recent Developments

  • In October 2023, Boston Scientific Corporation received approval for the POLARx Cryoablation System by the U.S. Food and Drug Administration (FDA). This system features the POLARx FIT Cryoablation Balloon Catheter, which can treat patients with paroxysmal atrial fibrillation (AF) by enabling two different balloon sizes in one catheter.

  • In August 2023, Biosense Webster received approval for various atrial fibrillation ablation products that can be utilized in a workflow without fluoroscopy during catheter ablation procedures.

  • In May 2023, Abbott obtained approval from the U.S. Food and Drug Administration (FDA) for TactiFlex Ablation Catheter, Sensor Enabled, the first ablation catheter with contact force technology and a flexible tip. The TactiFlex catheter can treat atrial fibrillation (AFib) with reduced procedure times and better safety than previous-generation catheters.

  • In February 2022, Boston Scientific Corp. acquired Baylis Medical Company Inc., specializing in advanced transseptal solutions for the left side of the heart in catheter-based procedures.

Electrophysiology Devices Market Report Scope

Report Attribute


Market size value in 2024

USD 11.48 billion

Revenue forecast in 2030

USD 25.02 billion

Growth rate

CAGR of 13.9% from 2024 to 2030

Base year for estimation


Historical data

2018 - 2022

Forecast period

2024 - 2030 

Quantitative units

Revenue in USD million/billion and CAGR from 2024 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, trends

Segments covered

Device type, indication, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Mexico; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Boston Scientific Corp.; Medtronic; Abbott; Biosense Webster (Johnson & Johnson Services, Inc.); Biotronik; General Electric Company; Siemens Healthcare AG; MicroPort Scientific Corporation; Koninklijke Philips N.V.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Electrophysiology Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global electrophysiology (EP) devices market report on the basis of device type , indication, end-use, and region:

Global Electrophysiology Devices Market Report Segmentation

  • Device Type Outlook (Revenue, USD Million, 2018 - 2030)

    • Ablation Catheters

      • Radiofrequency (RF) Ablation

      • Cryoablation

      • Pulse Field Ablation

    • Diagnostic Catheters

    • Laboratory Devices

    • Access Devices

  • Indication Outlook (Revenue, USD Million, 2018 - 2030)

    • Atrial Fibrillation (AF)

    • Non-Atrial Fibrillation

  • End-use Outlook (Revenue, USD Million, 2018 - 2030)

    • Inpatient Facilities

    • Outpatient Facilities

    • Others

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Thailand

    • Latin America

      • Mexico

      • Brazil

      • Argentina

    • Middle East & Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.